Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 16 |
| List of Tables | 15 | 2 |
| List of Figures | 17 | 1 |
| Introduction | 18 | 1 |
| Global Markets Direct Report Coverage | 18 | 1 |
| Osteoarthritis Overview | 19 | 1 |
| Therapeutics Development | 20 | 2 |
| Pipeline Products for Osteoarthritis Overview | 20 | 1 |
| Pipeline Products for Osteoarthritis Comparative Analysis | 21 | 1 |
| Osteoarthritis Therapeutics under Development by Companies | 22 | 5 |
| Osteoarthritis Therapeutics under Investigation by Universities/Institutes | 27 | 1 |
| Osteoarthritis Pipeline Products Glance | 28 | 3 |
| Late Stage Products | 28 | 1 |
| Clinical Stage Products | 29 | 1 |
| Early Stage Products | 30 | 1 |
| Osteoarthritis Products under Development by Companies | 31 | 6 |
| Osteoarthritis Products under Investigation by Universities/Institutes | 37 | 1 |
| Osteoarthritis Companies Involved in Therapeutics Development | 38 | 56 |
| A. Menarini Industrie Farmaceutiche Riunite Srl | 38 | 1 |
| AbbVie Inc | 39 | 1 |
| Abiogen Pharma S.p.A. | 40 | 1 |
| Ablynx NV | 41 | 1 |
| Achelios Therapeutics, Inc. | 42 | 1 |
| Addex Therapeutics Ltd | 43 | 1 |
| Amgen Inc. | 44 | 1 |
| Amura Holdings Limited | 45 | 1 |
| Arcarios BV | 46 | 1 |
| Asahi Kasei Pharma Corp. | 47 | 1 |
| Asklepios BioPharmaceutical, Inc. | 48 | 1 |
| Astellas Pharma Inc. | 49 | 1 |
| Asterias Biotherapeutics, Inc. | 50 | 1 |
| Biopharm GmbH | 51 | 1 |
| Bone Therapeutics SA | 52 | 1 |
| Can-Fite BioPharma Ltd. | 53 | 1 |
| Cardax Pharmaceuticals, Inc. | 54 | 1 |
| Cellceutix Corporation | 55 | 1 |
| Cellular Biomedicine Group, Inc. | 56 | 1 |
| Evgen Pharma Plc | 57 | 1 |
| Galapagos NV | 58 | 1 |
| Genequine Biotherapeutics GmbH | 59 | 1 |
| GlaxoSmithKline Plc | 60 | 1 |
| IntelliCell BioSciences Inc. | 61 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 62 | 1 |
| Jenrin Discovery, Inc. | 63 | 1 |
| K-Stemcell Co., Ltd. | 64 | 1 |
| Levolta Pharmaceuticals, Inc. | 65 | 1 |
| Medivir AB | 66 | 1 |
| Merck KGaA | 67 | 1 |
| Mesoblast Limited | 68 | 1 |
| Mor Research Application Ltd | 69 | 1 |
| NicOx S.A. | 70 | 1 |
| Nordic Bioscience A/S | 71 | 1 |
| Novartis AG | 72 | 1 |
| Omeros Corporation | 73 | 1 |
| Ono Pharmaceutical Co., Ltd. | 74 | 1 |
| OrthoCyte Corporation | 75 | 1 |
| Osteologix Holdings Plc. | 76 | 1 |
| Pfizer Inc. | 77 | 1 |
| Pharmalink AB | 78 | 1 |
| Philogen S.p.A. | 79 | 1 |
| PLx Pharma Inc. | 80 | 1 |
| ProteoThera, Inc. | 81 | 1 |
| Regeneus Ltd | 82 | 1 |
| Seikagaku Corporation | 83 | 1 |
| STELIS Biopharma Pvt. Ltd. | 84 | 1 |
| Symic Biomedical, Inc. | 85 | 1 |
| Takeda Pharmaceutical Company Limited | 86 | 1 |
| TissueGene, Inc. | 87 | 1 |
| Upsher-Smith Laboratories, Inc. | 88 | 1 |
| Yooyoung Pharmaceutical Co., Ltd. | 89 | 1 |
| Yuhan Corporation | 90 | 1 |
| Yungjin Pharm. Co., Ltd. | 91 | 1 |
| Zimmer Biomet Holdings, Inc. | 92 | 1 |
| Zynerba Pharmaceuticals, Inc. | 93 | 1 |
| Osteoarthritis Therapeutics Assessment | 94 | 14 |
| Assessment by Monotherapy Products | 94 | 1 |
| Assessment by Combination Products | 95 | 1 |
| Assessment by Target | 96 | 4 |
| Assessment by Mechanism of Action | 100 | 4 |
| Assessment by Route of Administration | 104 | 2 |
| Assessment by Molecule Type | 106 | 2 |
| Drug Profiles | 108 | 148 |
| (apocynin + paeonol) Drug Profile | 108 | 1 |
| (clodronate disodium + hyaluronic acid) Drug Profile | 109 | 1 |
| 4-P004 Drug Profile | 110 | 1 |
| ABT-981 Drug Profile | 111 | 1 |
| ALLO-ASC Drug Profile | 112 | 1 |
| AlloJoin Drug Profile | 113 | 1 |
| AM-3701 Drug Profile | 114 | 1 |
| AM-3876 Drug Profile | 115 | 1 |
| Anatabine Drug Profile | 116 | 3 |
| Antibody for Osteoarthritis Drug Profile | 119 | 1 |
| Antibody to Inhibit TGF-Beta 1 for Osteoarthritis Drug Profile | 120 | 1 |
| ARC-118 Drug Profile | 121 | 1 |
| AS-001 Drug Profile | 122 | 1 |
| ASP-7962 Drug Profile | 123 | 1 |
| BNP-OA Drug Profile | 124 | 1 |
| BRM-421 Drug Profile | 125 | 1 |
| CDX-085 Drug Profile | 126 | 2 |
| celecoxib Drug Profile | 128 | 1 |
| CHND-1 Drug Profile | 129 | 1 |
| clodronate disodium Drug Profile | 130 | 1 |
| CR-8357 Drug Profile | 131 | 1 |
| CRB-0017 Drug Profile | 132 | 1 |
| CS-30MS02 Drug Profile | 133 | 1 |
| DA-5202 Drug Profile | 134 | 1 |
| denosumab Drug Profile | 135 | 9 |
| DIS-BIO-EPS Drug Profile | 144 | 1 |
| DNX-314 Drug Profile | 145 | 1 |
| Drug for Bone Diseases and Osteoarthritis Drug Profile | 146 | 1 |
| Drug for Osteoarthritis Drug Profile | 147 | 1 |
| Drugs to Inhibit Renin Angiotensin for Osteoarthritis Drug Profile | 148 | 1 |
| Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture Drug Profile | 149 | 1 |
| Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders Drug Profile | 150 | 1 |
| fasitibant chloride Drug Profile | 151 | 1 |
| GLPG-1972 Drug Profile | 152 | 1 |
| GQ-203 Drug Profile | 153 | 1 |
| GQ-303 Drug Profile | 154 | 1 |
| GSK-2394002 Drug Profile | 155 | 1 |
| JD-4000 Series Drug Profile | 156 | 1 |
| JTA-004 Drug Profile | 157 | 1 |
| Kartogenin Drug Profile | 158 | 1 |
| KBP-056 Drug Profile | 159 | 1 |
| ketoprofen Drug Profile | 160 | 2 |
| KM-278 Drug Profile | 162 | 1 |
| LEVI-04 Drug Profile | 163 | 1 |
| LH-023 Drug Profile | 164 | 1 |
| LNA-043 Drug Profile | 165 | 1 |
| MIV-711 Drug Profile | 166 | 2 |
| Monoclonal Antibodies for Inflammation and Osteoarthritis Drug Profile | 168 | 1 |
| Monoclonal Antibody Conjugates for Osteoarthritis Drug Profile | 169 | 1 |
| Monoclonal Antibody for Osteoarthritis Drug Profile | 170 | 1 |
| MOR-106 Drug Profile | 171 | 1 |
| MPC-75IA Drug Profile | 172 | 1 |
| naproxcinod Drug Profile | 173 | 3 |
| NBS-101 Drug Profile | 176 | 1 |
| NStride APS Drug Profile | 177 | 1 |
| ONO-4474 Drug Profile | 178 | 1 |
| OTXCP-03 Drug Profile | 179 | 1 |
| OTXCP-07 Drug Profile | 180 | 1 |
| Peptide for Osteoarthritis Drug Profile | 181 | 1 |
| PF-152 Drug Profile | 182 | 1 |
| piclidenoson Drug Profile | 183 | 7 |
| PL-1100 Drug Profile | 190 | 1 |
| PN-6047 Drug Profile | 191 | 1 |
| PRO-1 Drug Profile | 192 | 1 |
| Progenza Drug Profile | 193 | 1 |
| Protein for Osteoarthritis and Asthma Drug Profile | 194 | 1 |
| Protein for Rheumatoid Arthritis and Osteoarthritis Drug Profile | 195 | 1 |
| Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile | 196 | 2 |
| PRX-167700 Drug Profile | 198 | 1 |
| Recombinant Peptides for Osteoarthritis Drug Profile | 199 | 1 |
| Recombinant Protein for Osteoarthritis Drug Profile | 200 | 1 |
| Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis Drug Profile | 201 | 1 |
| Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS Drug Profile | 202 | 1 |
| ReJoin Drug Profile | 203 | 4 |
| Salmon Calcitonin Drug Profile | 207 | 2 |
| SB-061 Drug Profile | 209 | 1 |
| SBL-005 Drug Profile | 210 | 1 |
| SI-613 Drug Profile | 211 | 1 |
| SM-04690 Drug Profile | 212 | 2 |
| Small Molecule for Degenerative Arthritis Drug Profile | 214 | 1 |
| Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders Drug Profile | 215 | 1 |
| Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis Drug Profile | 216 | 1 |
| Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders Drug Profile | 217 | 1 |
| Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders Drug Profile | 218 | 1 |
| Small Molecules for Osteoarthritis Drug Profile | 219 | 1 |
| Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders Drug Profile | 220 | 1 |
| Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis Drug Profile | 221 | 1 |
| Small Molecules to Inhibit iNOS for Osteoarthritis Drug Profile | 222 | 1 |
| Small Molecules to Inhibit MMP-13 for Osteoarthritis Drug Profile | 223 | 1 |
| sprifermin Drug Profile | 224 | 2 |
| Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis Drug Profile | 226 | 1 |
| Stem Cell Therapy for Autoimmune Diseases Drug Profile | 227 | 2 |
| Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Drug Profile | 229 | 1 |
| Stem Cell therapy for CNS, CVS, Dermatological, Immunological and Metabolic Disorders Drug Profile | 230 | 1 |
| Stem Cell Therapy for Osteoarthritis Drug Profile | 231 | 1 |
| Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis Drug Profile | 232 | 1 |
| Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases Drug Profile | 233 | 1 |
| Sulforadex Drug Profile | 234 | 2 |
| tonogenchoncel-L Drug Profile | 236 | 3 |
| TPX-100 Drug Profile | 239 | 2 |
| TRBN-0224 Drug Profile | 241 | 2 |
| UGP-302 Drug Profile | 243 | 2 |
| VOLT-01 Drug Profile | 245 | 1 |
| X-0002 Drug Profile | 246 | 2 |
| XT-101 Drug Profile | 248 | 1 |
| XT-150 Drug Profile | 249 | 1 |
| YH-14619 Drug Profile | 250 | 1 |
| YRA-1909 Drug Profile | 251 | 1 |
| YY-1201 Drug Profile | 252 | 1 |
| ZYN-002 Drug Profile | 253 | 3 |
| Osteoarthritis Dormant Projects | 256 | 10 |
| Osteoarthritis Discontinued Products | 266 | 2 |
| Osteoarthritis Product Development Milestones | 268 | 12 |
| Featured News &Press Releases | 268 | 1 |
| Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures | 268 | 1 |
| Jun 13, 2016: Symic Advances Product Candidate SB-061 into Clinical Development for the Treatment of Osteoarthritis | 269 | 1 |
| May 17, 2016: Regeneus completes enrolment, positive safety review in stem cell trial | 270 | 1 |
| May 05, 2016: Rock Creek Pharmaceuticals Announces Japanese, European and U.S. Patent Developments and Valuation Initiative for Lead Compound | 271 | 1 |
| Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid | 272 | 1 |
| Apr 01, 2016: Mesoblast Cell Therapy Shows Disease Modifying Effects On Knee Osteoarthritis | 273 | 1 |
| Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer | 274 | 1 |
| Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis | 275 | 1 |
| Jan 13, 2016: Cellular Biomedicine Group Announces Positive 48-Week Data from Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy | 275 | 1 |
| Jan 06, 2016: Launch of Phase I clinical Trial for AlloJoin Off-the-Shelf Allogeneic Stem Cell Therapy for KOA | 276 | 1 |
| Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial | 277 | 1 |
| Dec 22, 2015: Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for ReJoin | 278 | 1 |
| Dec 16, 2015: Symic Receives New U.S. Patent for Osteoarthritis Program | 278 | 1 |
| Nov 20, 2015: Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives EU3.5 million milestone from Servier | 278 | 1 |
| Nov 17, 2015: Symic Biomedical Selects Osteoarthritis Clinical Candidate | 279 | 1 |
| Appendix | 280 | 2 |
| Methodology | 280 | 1 |
| Coverage | 280 | 1 |
| Secondary Research | 280 | 1 |
| Primary Research | 280 | 1 |
| Expert Panel Validation | 280 | 1 |
| Contact Us | 280 | 1 |
| Disclaimer | 281 | 1 |